Journal of Renal Nutrition
Volume 20, Issue 1 , Pages 1-7, January 2010

Systematic Review of Evidence for the Use of Intradialytic Parenteral Nutrition in Malnourished Hemodialysis Patients

  • Mhairi K. Sigrist, BSc, PhD

      Affiliations

    • Department of Nephrology, University of British Columbia, St. Paul's Hospital, Vancouver, British Columbia, Canada
    • Corresponding Author InformationAddress reprint requests to Mhairi K. Sigrist, Department of Nephrology, St. Paul's Hospital, University of British Columbia, Providence Health, 1081 Burrard St., Rm. 6010A, Vancouver, British Columbia, Canada. V6K 1C6.
  • ,
  • Adeera Levin, MD, FRCP

      Affiliations

    • Department of Nephrology, University of British Columbia, St. Paul's Hospital, Vancouver, British Columbia, Canada
  • ,
  • Aaron M. Tejani, BSc(pharm), PharmD, ACPR

      Affiliations

    • Clinical Research and Drug Information, Fraser Health Pharmacy Services, Fraser Valley, British Columbia, Canada

published online 29 September 2009.

Objective

Intradialytic parenteral nutrition (IDPN) is widely used to treat malnourished hemodialysis (HD) patients. However, the benefits of this treatment are unknown. Moderate protein-energy malnutrition (PEM) is thought to affect 15% to 43% of maintenance HD patients, and is independently associated with mortality in this population. This study systematically reviews the current literature, to assess whether IDPN improves survival, quality of life, or nutritional status in those receiving maintenance HD.

Methods

Two investigators undertook a formal systematic review of the literature, using the following key search words: intradialytic parenteral nutrition or intradialytic total parenteral nutrition plus any combination of renal dialysis or kidney-failure or chronic kidney disease and parenteral nutrition or intravenous nutrition or intravenous feeding.

Results

The search identified three suitable randomized, controlled trials, only one of which investigated hard clinical endpoints. There were insufficient data to undertake a meta-analysis.

Conclusions

The evidence from clinical studies is insufficient to demonstrate either a net benefit or a net harm associated with the providing IDPN to malnourished HD patients. We recommend that any patient in whom IDPN was deemed necessary be entered into a clinical trial or registry, to record hard clinical outcomes associated with the use of this treatment.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1051-2276(09)00217-9

doi:10.1053/j.jrn.2009.08.003

Journal of Renal Nutrition
Volume 20, Issue 1 , Pages 1-7, January 2010